{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,16]],"date-time":"2025-10-16T20:45:04Z","timestamp":1760647504842,"version":"3.37.1"},"reference-count":4,"publisher":"American College of Physicians","issue":"10","license":[{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.acpjournals.org\/journal\/aim\/text-and-data-mining"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Ann Intern Med"],"published-print":{"date-parts":[[2021,10]]},"DOI":"10.7326\/acpj202110190-111","type":"journal-article","created":{"date-parts":[[2021,10,5]],"date-time":"2021-10-05T00:08:47Z","timestamp":1633392527000},"page":"JC111","source":"Crossref","is-referenced-by-count":4,"title":["Tofacitinib reduced death or respiratory failure at 28 d in patients hospitalized with COVID-19 pneumonia"],"prefix":"10.7326","volume":"174","author":[{"given":"Steven Y.C.","family":"Tong","sequence":"first","affiliation":[{"name":"University of Melbourne at the Peter Doherty Institute for Infection and Immunity, Melbourne, Victoria, Australia (S.Y.T., N.P.)"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Neta","family":"Petersiel","sequence":"additional","affiliation":[{"name":"University of Melbourne at the Peter Doherty Institute for Infection and Immunity, Melbourne, Victoria, Australia (S.Y.T., N.P.)"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"4285","reference":[{"key":"ACPJ202110190-111-R1","doi-asserted-by":"crossref","unstructured":"RECOVERY Collaborative Group; Horby P, Lim WS, Emberson JR, et al. Dexamethasone in hospitalized patients with Covid-19. N Engl J Med. 2021;384:693-704. [PMID: 32678530]","DOI":"10.1056\/NEJMoa2021436"},{"key":"ACPJ202110190-111-R2","unstructured":"Kalil AC, Patterson TF, Mehta AK, et al. Baricitinib plus remdesivir for hospitalized adults with Covid-19. N Engl J Med. 2021;384:795-807. [PMID: 33306283]"},{"key":"ACPJ202110190-111-R3","unstructured":"RECOVERY Collaborative Group. Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. Lancet. 2021;397:1637-45. [PMID: 33933206]"},{"key":"ACPJ202110190-111-R4","doi-asserted-by":"crossref","unstructured":"REMAP-CAP Investigators; Gordon AC, Mouncey PR, Al-Beidh F, et al. Interleukin-6 receptor antagonists in critically ill patients with Covid-19. N Engl J Med. 2021;384:1491-1502. [PMID: 33631065]","DOI":"10.1056\/NEJMoa2100433"}],"container-title":["Annals of Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.acpjournals.org\/doi\/pdf\/10.7326\/ACPJ202110190-111","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.acpjournals.org\/doi\/full-xml\/10.7326\/ACPJ202110190-111","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,2,14]],"date-time":"2025-02-14T22:21:49Z","timestamp":1739571709000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.acpjournals.org\/doi\/10.7326\/ACPJ202110190-111"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10]]},"references-count":4,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2021,10]]}},"alternative-id":["10.7326\/ACPJ202110190-111"],"URL":"https:\/\/doi.org\/10.7326\/acpj202110190-111","relation":{},"ISSN":["0003-4819","1539-3704"],"issn-type":[{"type":"print","value":"0003-4819"},{"type":"electronic","value":"1539-3704"}],"subject":[],"published":{"date-parts":[[2021,10]]}}}